Singapore biomedical R&D strong despite wider downturn
This article was originally published in Scrip
The private sector still appears to have faith in the attractions of Singapore as a place to carry out research, at least if the latest official figures are anything to go by. Total business expenditure on R&D in the city-state's biomedical sciences sector rose by 24% last year, to S$527.7 million ($405.9 million).
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context